Etropal ADXBUL:ETR 50 Interest Coverage is 3.07 as of Dec. 2025, which is 121% above its 10-year median of 1.39. GuruFocus rates XBUL:ETR with a GF Score™ of 50/100 and a GF Value™ of €8.57 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 466 Medical Devices & Instruments companies, Etropal AD ranks worse than 83.69% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Etropal AD's
Operating Income
for the
six
months ended in Dec. 2025 was €0.45 Mil. Etropal AD's Interest Expense for the
six
months ended in Dec. 2025 was €-0.15 Mil.
Etropal AD's interest coverage for the quarter that ended in Dec. 2025 was 3.07.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Etropal AD's Interest Coverage or its related term are showing as below:
XBUL:ETR'
s Interest Coverage Range Over the Past 10 Years
Min: 0.54 Med: 1.39 Max: 3.07
Current: 3.07
XBUL:ETR's Interest Coverage is ranked worse than 83.69% of 466
companies
in the Medical Devices & Instruments industry
Industry Median: 15.875
vs XBUL:ETR: 3.07
Etropal AD (XBUL:ETR) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Etropal AD Interest Coverage Related Terms
Etropal AD Interest Coverage Historical Data
* Premium members only.
The historical data trend for Etropal AD's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XBUL:ETR vs ISRG, BDX, MDLN: Interest Coverage Comparison
For the Medical Instruments & Supplies subindustry, Etropal AD's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Etropal AD Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Etropal AD's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Etropal AD's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Etropal AD (XBUL:ETR) has a Interest Coverage of 3.07 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Etropal AD and its competitors. This is 121% above median its historical median of 1.39. Over the past decade, Etropal AD's Interest Coverage has ranged from 0.54 to 3.07. According to the industry distribution chart, Etropal AD ranks #390 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 83.7%.
Is Etropal AD's Interest Coverage too high?
Etropal AD's current Interest Coverage of 3.07 is 121% above median its 10-year median of 1.39. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 3.07. The Medical Devices & Instruments industry median Interest Coverage is 15.88. Etropal AD's value of 3.07 is 80.7% below this industry median. Based on the distribution chart, Etropal AD ranks #390 out of 466 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Etropal AD has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Etropal AD's Interest Coverage compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Etropal AD ranks #390 out of 466 companies for Interest Coverage. This places Etropal AD in the lower half of its industry. The industry median Interest Coverage is 15.88. Etropal AD's value of 3.07 is 80.7% below this benchmark. Historically, Etropal AD's own Interest Coverage has ranged from 0.54 to 3.07 over the past decade. While the company's 10-year median is 1.39 vs. the industry median of 15.88, Etropal AD has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 15.88, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Etropal AD's current Interest Coverage of 3.07 is 80.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Etropal AD and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 15.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Etropal AD's current Interest Coverage is 3.07, which is 121% above median its own 10-year median of 1.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Etropal AD stock overvalued right now?
Based on GuruFocus' analysis, Etropal AD (XBUL:ETR) is currently considered Significantly Undervalued. The stock's GF Value™ is €8.57, compared to a current price of €2.52 — trading 70.6% below its estimated fair value. The current Interest Coverage is 3.07, which is 121% above median its 10-year median of 1.39 and 80.7% below the Medical Devices & Instruments industry median of 15.88. Etropal AD's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Etropal AD (XBUL:ETR), the current Interest Coverage is 3.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Etropal AD (XBUL:ETR) Overvalued in 2026?
Based on GuruFocus' analysis, Etropal AD stock appears to be undervalued.
The current stock price of €2.52 is trading 70.6% below its estimated GF Value™ of €8.57.
GuruFocus considers Etropal AD to be Significantly Undervalued.
Key valuation signals for XBUL:ETR:
Interest Coverage: 3.07 (121% above median its 10-year median of 1.39)
GF Value™: €8.57 vs. price of €2.52 (70.6% below fair value)
Industry Position: 80.7% below the Medical Devices & Instruments median (#390 of 466)
No single metric tells the full story. See the XBUL:ETR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.
50GF Score
Get the complete analysis for XBUL:ETR
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:ETR has been successfully added to your 
